PMID- 30738957
OWN - NLM
STAT- MEDLINE
DCOM- 20190531
LR  - 20190531
IS  - 1873-0183 (Electronic)
IS  - 1568-9972 (Linking)
VI  - 18
IP  - 4
DP  - 2019 Apr
TI  - Immune checkpoints and the regulation of tolerogenicity in dendritic cells: 
      Implications for autoimmunity and immunotherapy.
PG  - 359-368
LID - S1568-9972(19)30032-1 [pii]
LID - 10.1016/j.autrev.2019.02.006 [doi]
AB  - The immune system is responsible for defending the host from a large variety of 
      potential pathogens, while simultaneously avoiding immune reactivity towards 
      self-components. Self-tolerance has to be tightly maintained throughout several 
      central and peripheral processes; immune checkpoints are imperative for 
      regulating the immunity/tolerance balance. Dendritic cells (DCs) are specialized 
      cells that capture antigens, and either activate or inhibit antigen-specific T 
      cells. Therefore, they play a key role at inducing and maintaining immune 
      tolerance. DCs that suppress the immune response have been called tolerogenic 
      dendritic cells (tolDCs). Given their potential as a therapy to prevent 
      transplant rejection and autoimmune damage, several strategies are under 
      development to generate tolDCs, in order to avoid activation and expansion of 
      self-reactive T cells. In this article, we summarize the current knowledge 
      relative to the main features of tolDCs, their mechanisms of action and their 
      therapeutic use for autoimmune diseases. Based on the literature reviewed, 
      autologous antigen-specific tolDCs might constitute a promising strategy to 
      suppress autoreactive T cells and reduce detrimental inflammatory processes.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Funes, Samanta C
AU  - Funes SC
AD  - Millennium Institute on Immunology and Immunotherapy, Departamento de Genetica 
      Molecular y Microbiologia, Facultad de Ciencias Biologicas, Pontificia 
      Universidad Catolica de Chile, Santiago, Chile. Electronic address: 
      samanta.celeste@uc.cl.
FAU - Manrique de Lara, Amaranta
AU  - Manrique de Lara A
AD  - Millennium Institute on Immunology and Immunotherapy, Departamento de Genetica 
      Molecular y Microbiologia, Facultad de Ciencias Biologicas, Pontificia 
      Universidad Catolica de Chile, Santiago, Chile; Instituto de Biotecnologia, 
      Centro de Ciencias Genomicas, Universidad Nacional Autonoma de Mexico, 
      Cuernavaca, Morelos, Mexico. Electronic address: amanriqu@lcg.unam.mx.
FAU - Altamirano-Lagos, Maria J
AU  - Altamirano-Lagos MJ
AD  - Millennium Institute on Immunology and Immunotherapy, Departamento de Genetica 
      Molecular y Microbiologia, Facultad de Ciencias Biologicas, Pontificia 
      Universidad Catolica de Chile, Santiago, Chile. Electronic address: 
      mj.altamirano@uc.cl.
FAU - Mackern-Oberti, Juan P
AU  - Mackern-Oberti JP
AD  - Instituto de Medicina y Biologia Experimental de Cuyo, IMBECU, CONICET, Mendoza, 
      Argentina; Instituto de Fisiologia, Facultad de Ciencias Medicas, Universidad 
      Nacional de Cuyo, Mendoza, Argentina. Electronic address: 
      jpmackern@mendoza-conicet.gob.ar.
FAU - Escobar-Vera, Jorge
AU  - Escobar-Vera J
AD  - Laboratorio de Genetica, Departamento Biomedico, Facultad de Ciencias de la 
      Salud, Universidad de Antofagasta, Antofagasta, Chile. Electronic address: 
      jorge.escobar@uantof.cl.
FAU - Kalergis, Alexis M
AU  - Kalergis AM
AD  - Millennium Institute on Immunology and Immunotherapy, Departamento de Genetica 
      Molecular y Microbiologia, Facultad de Ciencias Biologicas, Pontificia 
      Universidad Catolica de Chile, Santiago, Chile; Departamento de Endocrinologia, 
      Escuela de Medicina, Facultad de Medicina, Pontificia Universidad Catolica de 
      Chile, Santiago, Chile. Electronic address: akalergis@bio.puc.cl.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190208
PL  - Netherlands
TA  - Autoimmun Rev
JT  - Autoimmunity reviews
JID - 101128967
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Autoimmunity/immunology/*physiology
MH  - Cell Cycle Checkpoints/*immunology
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immune Tolerance/*physiology
MH  - Immunotherapy/*methods
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Self Tolerance
MH  - T-Lymphocytes/immunology
OTO - NOTNLM
OT  - Autoimmunity
OT  - Immune checkpoints
OT  - Immunotherapy
OT  - Tolerance
OT  - Tolerogenic dendritic cells
EDAT- 2019/02/11 06:00
MHDA- 2019/06/01 06:00
CRDT- 2019/02/11 06:00
PHST- 2019/02/11 06:00 [pubmed]
PHST- 2019/06/01 06:00 [medline]
PHST- 2019/02/11 06:00 [entrez]
AID - S1568-9972(19)30032-1 [pii]
AID - 10.1016/j.autrev.2019.02.006 [doi]
PST - ppublish
SO  - Autoimmun Rev. 2019 Apr;18(4):359-368. doi: 10.1016/j.autrev.2019.02.006. Epub 
      2019 Feb 8.